• Vaccine Ontology ID: VO_0004686
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Cattle
• Preparation: BoHV-4-based vector cloned as a bacterial artificial chromosome (BAC) was engineered to express the bluetongue virus (BTV) immune-dominant glycoprotein VP2 provided of a heterologous signal peptide to its amino terminal and a trans-membrane domain to its carboxyl terminal (IgK-VP2gDtm), to allow VP2 expression targeting to the cell membrane fraction (Franceschi et al., 2011).
• Immunization Route: Other

Mouse Response

• Host Strain: α/β interferon receptor knockout (IFNAR(-/-)) mice
• Vaccination Protocol: IFNAR(-/-) mice intraperitoneally inoculated twice with BoHV-4-A-IgK-VP2gDtm at different time points.
• Vaccine Immune Response Type: VO_0000287
• Immune Response: Mice eveloped serum neutralizing antibodies against BTV .
• Side Effects: A pre-challenge experiment was performed to test BoHV-4 safety on adult α/β interferon receptor knockout (IFNAR(-/-)) mice, a newly generated bluetongue laboratory animal model. BoHV-4 infected IFNAR(-/-) mice did not show clinical signs even following the inoculation of BoHV-4 intra-cerebrally, although many areas of the brain got transduced (Franceschi et al., 2011).
• Challenge Protocol: a lethal dose of BTV-8 as used for challenge (Franceschi et al., 2011).
• Efficacy: Vaccinated mice showed a strongly reduced viremia and a longer survival time after challenge (Franceschi et al., 2011).